Vanguard Group Inc In8 Bio, Inc. Call Options Transaction History
Vanguard Group Inc
- $5.37 Trillion
- Q1 2025
Call Options
0 transactions
Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
---|---|---|---|---|---|
Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
Others Institutions Holding INAB
# of Institutions
29Shares Held
21.7MCall Options Held
0Put Options Held
0-
Bios Capital Management, LP Fort Worth, TX8.6MShares$1.2 Million1.8% of portfolio
-
Franklin Resources Inc San Mateo, CA5.7MShares$797,4680.0% of portfolio
-
Alyeska Investment Group, L.P. Chicago, IL2.08MShares$291,1400.0% of portfolio
-
Aigh Capital Management LLC Baltimore, MD1.45MShares$203,0000.13% of portfolio
-
Sigma Planning Corp Ann Arbor, MI701KShares$98,0950.0% of portfolio
About IN8BIO, INC.
- Ticker INAB
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 24,502,200
- Market Cap $3.43M
- Description
- IN8bio, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancers. Its lead product candidate includes INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of...